This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Biotech 2013 by the Numbers: A Blockbuster Year

NEW YORK (TheStreet) -- Hello, 2014! Before we crack open the new year, let's close the books on what was a very big 2013 in biotech investing.

And yes, investors did very well in biotech in 2013. This chart says it all:


IBB Chart
IBB data by YCharts

In a year where the markets outperformed, the biotech sector performed even better, posting returns not seen since 1999. Phenomenal. No wonder we saw a huge influx of generalist investors into healthcare stocks in 2013.

I'm a skeptic and always nagging readers about risk, so you know I have to point out something for biotech investors to worry about.

Biotech stocks underperformed the S&P 500 in the fourth quarter:


IBB Chart
IBB data by YCharts

Biotech stocks rallied in December but the significant selling in October could not be overcome.

Generic drug maker Lannett Co.  (LCI) was the sector's top-performing stock, with a return of 567%. Here's what that looks like in chart form:


LCI Chart
LCI data by YCharts

The rest of the Top 10:

Chelsea Therapeutics  (CHTP) 484%
Inovio Pharma  (INO) 481%
Puma Biotech  (PBYI) 452%
Acadia Pharma  (ACAD) 437%
BioCryst Pharma  (BCRX) 435%
Idera Pharma  (IDRA)420%
Arrowhead Research  (ARWR) 407%
Gentium  (GENT) 403%
Insys Therapeutics  (INSY) 400%

A single biotech and drug stock (Lannett) posted a six-fold bump in share price this year. Nine stocks increased in value by five times, 3 stocks quadrupled in value and 26 stocks tripled in value, according to S&P CapitalIQ.

Not all biotech and drug stocks fared so well in 2013: The biggest losers were:

Celsion  (CLSN) -89%
Aastrom Biosciences  (ASTM) -87%
Cardium Therapeutics  (CXM) -78%
Cel-Sci  (CVM) -78%
Aveo Pharma  (AVEO) -77%

Enjoy New Year's Day. Tomorrow, we'll get started covering biotech 2014.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,001.22 -38.27 -0.22%
S&P 500 1,988.40 -3.97 -0.20%
NASDAQ 4,538.5510 +6.4470 0.14%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs